Application and comparison of Fuhrman nuclear grading system with the novel tumor grading system for chromophobe renal cell carcinoma and its correlation with disease-specific events

Akash Pramod Sali1,2#, Ganesh K. Bahirwade1#, Ganesh Bakshi3, Gagan Prakash3, Amit Joshi4, Sangeeta B. Desai1, Santosh Menon1*

Departments of 1Pathology, 3Surgical Oncology and 4Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, 2Department of Pathology, Homi Bhabha Cancer Hospital (A Unit of Tata Memorial Centre), Sangrur, Punjab, India

#Both the authors have contributed equally to this manuscript.
*E-mail: mensantosh@gmail.com

INTRODUCTION

Renal cell carcinoma (RCC) accounts for approximately 2.2% of cases of the global cancer burden and about 1.8% of cases of global cancer-related mortality.1 It is estimated that RCC will account for approximately 2% overall cancer burden amongst Indian males.2 The common histologies encountered by a pathologist in RCC are the conventional clear cell RCC, papillary RCC, and chromophobe RCC (ChRCC). Although stage remains the most powerful prognosticator dictating the outcome, in smaller tumors,
the nuclear grade may aid in directing management and the follow-up or surveillance schedule (frequency of follow-up/abdominal contrast-enhanced computed tomography).\(^1\)\(^4\) Fuhrman nuclear grade (FNG) was the most widely used grading system for RCC until recently when the International Society for Urological Pathology (ISUP) proposed a new grading system.\(^5\) Some studies have even validated the clinical predictive value of FNG in RCC.\(^6\)\(^7\) Hence, the grading of RCC does have a prognostic significance and may aid in appropriate clinical management decisions.\(^8\)\(^9\) However, the usage of FNG is fraught with technical issues and cumbersome calculations of nuclear size, shape, and nucleoli, and hence, its utility in daily practice is limited to an assessment of nucleoli in practicality. The nuclear abnormalities of ChRCC nuclei are inherent to this tumor and hence, the applicability of FNG in ChRCC is controversial and may be inappropriate.\(^10\)\(^13\) Moreover, these two types of RCC have drastically different prognoses with 10-year survival for ChRCC ranging from 80% to 90% in contrast to clear cell RCC which ranges from 45% to 70%.\(^12\) To improve the grading of ChRCC, Paner et al. proposed an alternate grading system in the year 2010.\(^12\) Since then, various attempts have been made to validate this system.\(^14\)\(^19\) We undertook this study to evaluate the applicability and feasibility of this novel tumor grading system and compare it with the FNG system, as also with the disease-specific events.

### MATERIALS AND METHODS

This study was approved by the Institutional Ethics Committee (IEC Project no 1570). Retrospective analysis of consecutively diagnosed cases of ChRCC over 10 years (2005–2014) was done. Diagnosed cases of ChRCC on nephrectomy/partial nephrectomy specimens were included while the cases diagnosed on biopsy samples were excluded. Clinical and pathologic data evaluated were: Age, sex, and tumor size. The histopathology slides of ChRCC were retrieved and reviewed by two pathologists (SM and GKB). One of the reviewers (SM), a full-time dedicated genitourinary pathologist, was blinded to the clinical outcome and the status of nodal/distant metastasis. The important histopathological parameters examined were sarcomatous differentiation and necrosis. The tumor in each case was assigned an FNG as well as the novel chromophobe tumor grade (CTG)\(^12\) [Table 1]. The pathologic staging was assigned based on the AJCC 7th edition cancer staging manual. The follow-up data were obtained from clinical case records and electronic medical records. Correlation of the FNG and novel CTG system was done with pathological parameters and disease-free survival (DFS). The data were analyzed using SPSS software version 20.0 (IBM, Armonk, NY, USA). For assessing the association of various pathological variables, the Chi-square test, Fischer’s exact test, and Pearson’s correlation coefficient test were used. Survival curves were calculated using the Kaplan–Meier method.

Comparisons between curves were performed using the Mantel-Cox (log-rank) test. Both the grading systems were compared using receiver operating characteristics (ROC) curves. The area under the curve (AUC) and the 95% confidence intervals were noted. All the tests were applied at a 5% significance level.

### RESULTS

A total of 86 cases reported as ChRCC on nephrectomy specimens were retrieved. Out of these 86 cases, five cases were reclassified as clear cell RCC based on morphological and immunohistochemical findings and hence were excluded from the study cohort. One case with only slides from a recurrent ChRCC tumor was also excluded. The remaining cohort of 80 cases included both, the in-house operated \((n = 31; 38.8\%)\), and referral cases \((n = 49; 62.2\%)\). Seventy–three cases \((91.3\%)\) had undergone radical nephrectomy and four cases \((5\%)\) had partial nephrectomy specimens. Surgical details were not available in three cases \((3.8\%)\). The major clinicopathological variables are summarized in Supplementary Table 1. The median age was 52 years (range 27–77 years). Forty-four \((55\%)\) patients were male and 36 \((45\%)\) were female \((M:F = 1.2:1\). The mean tumor size was 10.38 cm (range 3 cm to 28 cm). Microscopically, necrosis was seen in 21 cases \((26.3\%)\) and sarcomatous differentiation was noted in nine cases \((11.3\%)\).

#### Grading of ChRCC with FNG and CTG

FNG had been assigned in 31 cases during initial reporting. Out of 22 cases initially graded as FNG-2, eight cases were re-assigned as FNG-3, one case was re-assigned as FNG-4, and 13 cases were confirmed as FNG-2. Out of seven cases initially reported as FNG-3, one case each was reassigned as FNG-2 and FNG-4, and the rest were retained as FNG-3. One case each initially graded as FNG-1 and FNG-4 were confirmed at the review. Hence, the distribution of FNG in the present cohort \((80\%)\) was as follow: FNG-1 \((n = 1; 1.3\%)\), FNG-2 \((n = 23; 28.3\%)\), FNG-3 \((n = 44; 55.0\%)\), and FNG-4 \((n = 12; 15.0\%)\). On applying CTG to the tumors, 48 cases \((60.0\%)\) were CTG-1, 20 cases \((25.0\%)\) were CTG-2, and 12 cases \((15.0\%)\) were CTG-3 [Figure 1]. CTG-3 cases included nine cases \((11.3\%)\) harboring sarcomatous differentiation. When FNG was compared with CTG, FNG-1 and FNG-4 corresponded to CTG-1 and CTG-3, respectively. All 23 cases of FNG-2 were assigned CTG-1. Of the 44 cases assigned FNG-3, 24 cases were downgraded to CTG-1, and 20 cases were placed in CTG-2 [Figure 2].

#### Staging (including pT stage, nodal status)

pT stage could be assigned in 51 cases; the distribution being as follows: pT1 \((n = 15; 29.4\%)\), pT2 \((n = 13; 25.5\%)\), and pT3 \((n = 23; 44.4\%)\). Upfront regional lymph node dissection was done in 40 cases, of which three cases \((3.8\%)\) showed nodal metastasis. Overall a complete TNM staging was possible in 38 cases. Twelve cases \((31.6\%)\) were stage
I, nine cases (23.7%) were stage II, 11 cases (28.9%) were stage III, and six cases (15.8%) were stage IV.

**Follow-up**

Follow-up was available in 46 cases. The median follow-up was 23.9 months (range 1–96.4 months). Five cases had metastasis at presentation (of which three cases had sarcomatous differentiation and two cases were nonsarcomatous). In addition, during follow-up, distant metastasis developed in 4 patients and local/locoregional recurrence occurred in three cases (two renal-bed recurrences and one paraaortic lymph node recurrence). The median time to recurrence/metastasis was 17.2 months (range 3.2 months to 31.2 months). The mean DFS for the whole group was 68.5 months. For analysis purpose, event time was taken as 1 month in the five cases which presented with metastasis (similar to Paner et al.).[12]
Correlation of grading system with DFS, recurrence, and metastasis

For the entire cohort, FNG and CTG had a statistically significant correlation with DFS ($P = 0.001$ and $P < 0.001$, respectively) [Supplementary Table 2 and Figure 3]. No event occurred in FNG-1 and FNG-2 tumors. The mean DFS of FNG-3 cases was 72.30 months and in FNG-4 cases it was 14.64 months. In contrast, no event occurred in CTG-1 tumors, whereas CTG-2 had a mean DFS of 44.51 months and CTG-3 had a mean DFS of 14.64 months. Univariate analysis, when applied only to nonsarcomatous cases, showed that CTG had a significant correlation with DFS ($P < 0.001$) in contrast to FNG ($P = 0.272$).

If only nonsarcomatous cases were taken into account, it was found that, as CTG increased there was a significant increase in the risk of disease-specific events (recurrence/metastasis) ($P = 0.001$) as against the FNG ($P = 0.106$). The ROC curve analysis was done for the whole cohort and nonsarcomatous cases separately. For the whole cohort, the AUC for CTG and FNG was 0.919 and 0.818, respectively, while for the nonsarcomatous cases the AUC for CTG and FNG was 0.903 and 0.724 respectively, [Supplementary Table 2].

**DISCUSSION**

The FNG was a widely used system for grading RCC including ChRCC until recently when Delahunt et al. questioned the utility of this grading system for ChRCC.[11] Attempts made by Lohse et al. to refine the FNG into a four-tier grading with an emphasis on nuclear prominence to suit ChRCC was not able to stratify the outcome in grades ≤3 tumors.[20] Later, Paner et al. proposed a novel grading system called CTG that did not take into account the nuclear characteristics (size and shape) of ChRCC.[12] There was a significant correlation between the CTG and the outcome.[12] This grading system was further validated in various studies conducted in different parts of the world,[14-19] Further, Cheville et al. established that although the CTG was associated with cancer-specific survival, it did not have an additional prognostic impact when the tumor stage and sarcomatous differentiation were evaluated.[15] We applied the CTG system to our cohort of patients and correlated it with disease-specific events.

The mean patient age (52.19 years) and the male-to-female ratio (1.2:1) in this study were comparable to earlier studies, wherein the mean age at presentation was 59 years.[21,22]

![Figure 3: Kaplan–Meier plots for disease-free survival, (a) Fuhrman nuclear grade; (b) chromophobe tumor grade](image)

| Table 2: Comparison of chromophobe tumor grading (CTG) assigned to Chromophobe Renal Cell Carcinoma in different studies |
| Authors (reference) | Paner et al.[12] | Finley et al.[14] | Cheville et al.[13] | Sperga et al.[16] | Weinzierl et al.[17] | Xie et al.[18] | Lin et al.[19] | Present study |
| Year | 2010 | 2011 | 2012 | 2013 | NA | 2014 | 2017 | 2019 | 2020 |
| Study Period | 1968-2005 (38 years) | 1992-2011 (20 years) | 1970-2006 (37 years) | 1997-2010 (14 years) | 2006-2015 (10 years) | 2000-2017 (18 years) | 2005-2014 |
| No. of Cases | 124 | 84 | 185 | 546 | 81 | 206 | 18 | 80 |
| CTG 1 | 92 (74%) | 40 (48.8%) | 140 (75%) | 252 (46.15%) | 52 (64%) | 142 (68%) | 14 (78%) | 48 (60%) |
| CTG 2 | 20 (16%) | 30 (36.5%) | 27 (15%) | 177 (32.41%) | 27 (34%) | 54 (26%) | 3 (17%) | 20 (25%) |
| CTG 3 | 12 (10%) | 12 (14.7%) | 18 (10%) | 84 (15.38%) | 02 (2%) | 13 (6%) | 1 (6%) | 12 (15%) |
| Follow-up (months: m, years: y) | Mean: 48m, Median: 37m, Range: 1m to 138.2m | Mean: 32.9m, Median: 10.5y, Range: 0.37m to 8.3y, | NA | Mean: 53m, Median: 48.4m, Range: 0.1m to 238m | 10.7m-129.9m | 70.6m, Median: 23.9m, Range: 3m to 105m | 10.3m, Median: 23.9m, Range: 1m to 96.4m |
| Outcome | R: 4, M: 15, | M: 8, | NA | R: 2, M: 1, M: 6, | DOD: 1 | DOD: 4 | DOD: 1 | |
| Recurrence (R), Metastases (M), Death due to disease (DOD) | DOD: 10 | | | | | | | |
The mean tumor size (10.38 cm) in this study, however, was larger as compared to those mentioned by Delahunt et al. (7.7 cm) and Amin et al. (8.0 cm).\[11,21\] The tendency of patients in our country to procrastinate seeking medical advice, due to logistical and financial constraints might be the reason for the larger tumor size at the presentation, in our series. The rate of necrosis (26.3%) and sarcomatous differentiation (11.25%) in our study is marginally more in comparison to Amin et al. (necrosis in 12.98% and sarcomatous differentiation in 8% cases).\[21\] Lower rates of sarcomatous differentiation in ChRCC have been reported by Cheville et al. (7% cases), and Przybycin et al. (2% cases).\[13,15\] The larger mean tumor size with a concomitant rise in chances of a sarcomatous differentiation and necrosis may be the reason for the slightly higher incidence of these aggressive histological features in our series.

Very few studies have evaluated FNG in ChRCC.\[10,14\] In most of these studies, the majority of ChRCC were assigned either FNG-2 or FNG-3 category. In our study, 44 cases (55%) were assigned FNG-3 on review of histopathology. Paner et al. placed as high as 74% of their ChRCC in the FNG-3 category in their series of 124 cases.\[12\] It is a well-established fact that ChRCC has lower malignant potential than conventional clear cell carcinoma and papillary RCC. Amin et al. in their study of 405 RCC cases found that clear cell carcinoma behaves aggressively than ChRCC,\[23\] Arguably then, FNG inevitably places ChRCC in higher grade owing to the inherent nuclear abnormalities seen in ChRCC. Thus, the FNG conveys a false overestimation of tumor nuclear grade to the treating genitourinary oncologists which may translate into unwarranted management and surveillance decisions. For the practicing pathologist, the application of FNG using the nuclear size in micrometer, shape, and nucleoli is cumbersome and fraught with variability. In comparison, applicability of CTG is based on geographical crowding and nuclear anaplasia which are easier to apply. In fact, most pathologists assign FNG based on nucleolar prominence at various magnifications of microscope which was the basis for ISUP nuclear grading. However, the ISUP nuclear grading does not apply to ChRCC.\[5\]

Few anecdotal studies have compared the FNG system and the grading system described by Paner et al.\[12,14,19\] The CTG respects the inherent nuclear abnormalities of ChRCC, as also the presence of areas of geographic crowding of nuclei. We conceptualize, based on our study, that the fluent application of CTG would require training on approximately 20–25 cases of ChRCC. Furthermore, the geographic innate crowding of nuclei adjacent to the tumor/renal capsule may lead to a false CTG-2 grading and should be kept in mind. The important feature not to be disregarded is that crowding has to be accompanied by nuclear (>3 times) and chromatin abnormalities. The majority of the cases in the present study were graded as CTG-1 (60%) with decreasing frequency to CTG-3 (15%). All sarcomatous cases were graded as CTG-3. These findings are similar to studies in the literature [Table 2].

In this study, the comparison between FNG and CTG yielded that these systems are comparable only at the ends of the grading spectrum, i.e., all FNG-1 and FNG-4 correspond to CTG-1 and CTG-3, respectively. However, ChRCC cases when graded by the CTG system were graded CTG-1 in almost 60% of cases. According to FNG, about 83.75% of cases were graded as FNG-2 and FNG-3. In contrast, with CTG all cases of FNG-2 were assigned CTG-1. The majority (55%) of the FNG-3 cases were downgraded to CTG-1 (54.54%) and CTG-2 (45.45%). Paner et al. compared FNG and CTG in their series and found that 93% of their cases were assigned FNG-2 or FNG-3, whereas by CTG 74% of cases were graded as CTG-1.\[12\] Finley et al. also demonstrate that majorituy of FNG-2 and FNG-3 cases downgrades to CTG-1 or CTG-2.\[14\] Thus, this study demonstrates that CTG provides an additional benefit in better stratification of FNG-2 and FNG-3 cases. This downgrade in CTG may translate into a modified clinical surveillance protocol as the stage-1 FNG-3 tumors might need a rigorous imaging follow-up schedule.\[24\]

On ROC curve analysis, CTG demonstrated higher grading accuracy than FNG as AUC for CTG was more than that for FNG in the whole cohort as well as in nonsarcomatous cases. Finley et al. also reported similar findings with superior AUC for CTG in comparison to FNG.\[14\]

The value of CTG over FNG is clearly demonstrated when they are correlated with DFS. Although we found a significant correlation between FNG and DFS in ChRCC, this association was lost, when only the nonsarcomatous cases were included. Notably, the mean DFS of FNG-3 cases of ChRCC in our series was as high as 72.3 months. On the contrary, CTG-2 and CTG-3 had a DFS of 44.51 months and 14.64 months respectively, again reiterating the fact of a false overgrading of ChRCC by the FNG system. We also noted that there was no correlation between the FNG and disease-specific adverse events like metastasis or recurrence in nonsarcomatous cases. These findings are in concordance with a study by Delahunt et al.\[11\] Paner et al. also found that CTG had a superior prognostic value than FNG and aided in identifying cases with potentially greater risk for disease progression.\[12\]

However, recently published studies validating CTG did not find a significant difference between the DFS of CTG-1 and CTG-2; on the contrary CTG-1 and CTG-2 when combined had a statistically significant different survival outcome as compared to CTG-3.\[17,18\] We were unable to validate this finding due to the lack of any disease-specific events in the CTG-1 subgroup. ChRCC has a better prognosis and is known to have a lower recurrence and metastasis rate; hence, only limited studies with longer follow-up have been able to adequately evaluate the CTG with other variables on a multiparametric analysis.\[13\] After excluding 12 sarcomatous cases, Paner et al. found that CTG was associated with the risk of adverse outcomes (P = 0.032), while FNG did not
show such association (P = 0.77). Further, Finley et al. reported that CTG was a significant predictor of outcome in univariate analysis (P = 0.025) when only nonsarcomatous cases were accounted for. We demonstrate similar findings in nonsarcomatous cases in this series.

The retrospective nature of the current study induces the inherent biases associated with such studies. Forty-nine (62%) of our cases had been operated outside and hence, adequate clinical details were not available in many of these cases. This referral bias also contributes to the lack of optimal staging details. Due to these reasons, TNM staging could be done only in 38 cases (47.5%). The multivariate analysis could not be done due to the limited number of disease-specific events and follow-up in the rest of the cases. The way to circumvent this issue is either a meta-analysis of studies with adequate follow-up or to evaluate the outcome in this tumor with exceptionally larger sample size. However, a single institutional study with a large sample size and availability of follow-up information in a relatively good proportion of cases is the strength of this study. The shorter time-frame for the inclusion of cases and the histopathological review by an experienced genitourinary pathologist ensured an explicit cohort of ChRCC in this study.

CONCLUSIONS

Our study emphasizes the futility of applying FNG in ChRCC. CTG, on the other hand, is a feasible option and is a better predictor of DFS and disease-specific adverse events than FNG.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. National Cancer Registry Programme. Available from: https://www.ncrindia.org/ncrp/ca/map.aspx. [Last accessed on 2020 Jul 31].
3. Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Postoperative surveillance for renal cell carcinoma: A multifactorial historical subtype specific protocol. BJU Int 2009;104:778-85.
4. Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: Development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 2013;64:472-7.
5. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, Mckinney J et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490-504.
6. Ficarra V, Prayet-Galetti T, Novella G, Bratti E, Maffei N, Dal Bianco M, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003;43:663-9.
7. Pantuck AJ, Zisman A, Beldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
8. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
9. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007;177:430-6.
10. Tickoo SK, Amin MB. Discriminant nuclear features of renal oncocyctoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis. Am J Clin Pathol 1998;110:782-7.
11. Delahunt B, Sika-Paotonu D, Bethwaite PB, McCreedie MR, Martignoni G, Eble JN, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 2007;31:957-60.
12. Paner GR, Amin MB, Alvarado-Cabrero I, Young AN, Strickler HJ, Moch H, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: Prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233-40.
13. Przybycien CG, Cronin AM, Darvishian F, Gopalan A, Al-Almadie HA, Fine SW, et al. Chromophobe renal cell carcinoma: A clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol 2011;35:962-70.
14. Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Affifi AA, et al. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol 2011;186:2168-74.
15. Cheville JC, Lohse CM, Sukov WR, Thompson RH, Leibovich BC. Chromophobe renal cell carcinoma: The impact of tumor grade on outcome. Am J Surg Pathol 2012;36:851-6.
16. Sperga M, Martinek P, Vanecek T, Grossmann P, Bauleth K, Perez-Montiel D, et al. Chromophobe renal cell carcinoma — Chromosomal aberration variability and its relation to Paner grading system: An array CGH and FISH analysis of 37 cases. Virchows Arch 2013;463:563-73.
17. Weinzierl EP, Thong AE, McKenney JK, Jeon SH, Chung BI. Relating prognosis in chromophobe renal cell carcinoma to the chromophobe tumor grading system. Korean J Urol 2014;55:239-44.
18. Xie Y, Ma X, Li H, Gao Y, Gu L, Chen L, et al. Prognostic value of clinical and pathological features in Chinese patients with chromophobe renal cell carcinoma: A 10-year single-center study. J Cancer 2017;8:3474-9.
19. Lin TF, Lin WR, Chen M, Dai SH, Sun FJ, Tsai WK, et al. Compare fuhrman nuclear and chromophobe tumor grade on chromophobe RCC. Open Med (Wars) 2019;14:336-42.
20. Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 2002;118:877-86.
21. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Strickler HJ, Lyles RH, et al. Chromophobe renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 2008;32:1822-34.
22. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: Clinicopathological features of 50 cases. J Urol 1995;154:964-7.
23. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker HJ, Moch H, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 2002;26:281-91.
24. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013;190:407-16.
| Variables                        | Values                                      |
|----------------------------------|---------------------------------------------|
| Age, Mean (range)                | 52.12 years (27-77 years)                  |
| Tumor size, Mean (range)         | 10.38 cm (3 cm-28 cm)                      |
| Sex, No. (%)                     |                                             |
| Male                            | 44 (55)                                    |
| Female                          | 36 (45)                                    |
| pT Stages, No. (%)               |                                             |
| pT1a                            | 6 (11.8)                                   |
| pT1b                            | 9 (17.6)                                   |
| pT2a                            | 2 (3.9)                                    |
| pT2b                            | 11 (21.6)                                  |
| pT3a                            | 18 (35.3)                                  |
| pT3b                            | 5 (9.8)                                    |
| pT4                             | 0                                          |
| Nodal Stages, No. (%)            |                                             |
| N0/Nx                           | 77 (96.2)                                  |
| N1                              | 3 (3.8)                                    |
| Metastasis, No. (%)              |                                             |
| Mx                              | 35 (43.8)                                  |
| M0                              | 40 (50)                                    |
| M1                              | 5 (6.3)                                    |
| TNM Stages                      |                                             |
| I                               | 12 (31.6%)                                 |
| II                              | 09 (23.7%)                                 |
| II                              | 11 (28.9%)                                 |
| IV                              | 6 (15.8%)                                  |
| Sarcomatous differentiation, No. |                                             |
| Absent                          | 71 (88.8)                                  |
| Present                         | 9 (11.3)                                   |
| Tumor Necrosis, No. (%)          |                                             |
| Absent                          | 59 (73.8)                                  |
| Present                         | 21 (26.3)                                  |


| Grading System | Grades | Correlation with DFS | ROC curve analysis for DFS | Non-Sarcomatous Cases | ROC curve analysis for DFS |
|----------------|--------|----------------------|----------------------------|------------------------|----------------------------|
| Fuhrman nuclear grade | Grade 1 | 1 0 NA 0.001 0.818 0.686-0.949 0.001 | 1 0 NA 0.272 0.724 0.550-0.889 0.063 | | |
| | Grade 2 | 13 0 NA | 13 0 NA | | |
| | Grade 3 | 27 6 72.30 | 27 6 72.30 | | |
| | Grade 4 | 8 6 14.64 | 2 1 31.24 | | |
| Chromophobe tumor grade | Grade 1 | 29 0 NA <0.001 0.919 0.884-0.994 <0.001 | 29 0 NA <0.001 0.903 0.813-0.993 0.001 | | |
| | Grade 2 | 12 6 44.51 (0.038) | 12 6 44.51 (0.046) | | |
| | Grade 3 | 8 6 14.64 | 2 1 31.24 | | |

DFS: Disease-free survival, NA: Not Available